PharmAthene, Inc. [PIP] has completed its acquisition of the biodefense vaccines business unit from the United Kingdom's Avecia Biologics in a deal that bolsters its portfolio of anthrax vaccine capabilities and gives it a potential product for plague vaccine. Terms of the deal include a $10 million cash payment and additional $7 million to be paid within 18 months of the closing. Avecia will also be able to receive payments up to $23 million contingent upon the achievement of certain…
Recommended
Trending
Congress Updates
Trump Wants Second Reconciliation Bill On His Desk By June 1
President Donald Trump on Wednesday called on Congress to pass and send a second reconciliation bill to his desk by June 1. The deadline follows congressional Republicans’ backing a pursuit […]
Upgrading Current GPS Ground System “Now a Viable Option,” As GPS OCX Problems Continue, Space Official Says
Upgrades to the GPS ground system–the Architecture Evolution Plan (AEP)–is an option under consideration by the Defense Department’s space acquisition chief, as problems continue in fielding the GPS Next Generation […]
Graham Says GOP To Move Ahead On Second Reconciliation Bill, With Defense Funds As Priority
Senate Budget Committee Chair Lindsey Graham (R-S.C.) said Wednesday, with the White House’s backing, his panel will move “expeditiously” on crafting a second reconciliation bill, citing priorities for defense and […]
Hegseth Acknowledges Potential $200 Billion Iran Supplemental Request, Final Figure ‘Could Move’
Defense Secretary Pete Hegseth on Thursday acknowledged the Pentagon could potentially ask Congress for $200 billion in supplemental funding to support the ongoing operation against Iran and replenish munitions used […]